• Anne Sabers, Katja Larsen, Susanne Blichfeldt, Lene Sahlholdt, and John Oskaer Rasmussen.
• Epilepsiklinikken, Glostrup Hospital, DK-2600 Glostrup. anns@glo.regionh.dk
• Ugeskr. Laeg. 2009 Jan 19; 171 (4): 221-5.

IntroductionTreatment with valproate is associated with an increased risk of teratogenicity compared to other antiepileptic drugs and can cause a complex of serious symptoms usually referred to as "foetal valproate symdrome" which is characterised by major and minor malformations in association with developmental delay. This paper aims to give attention to the syndrome through four case descriptions. Furthermore, possible risk factors and the use of the mutation 677C-T as a risk marker are discussed.Material And MethodsNine developmentally retarded children from a parent group, born of mothers who were treated with valproate during pregnancy, were neuropediatrically and neuropsychologically examined in a non-acute setting. The mothers were screened for the 677C-T mutation.ResultsFour of seven examined children fulfilled the criteria for foetal valproate syndrome. Only one of the four mothers was heterozygote for the 677C-T mutation (CT, n = 1/4) and none of the mothers were homozygote (TT, n = 0/4)ConclusionThe foetal valproate syndrome is a complex of symptoms which is probably underdiagnosed and should be considered in the diagnostic evaluation program for children with developmental delay who are born of mothers with epilepsy. The 677C-T mutation does not seem to be a useful genetic marker of this syndrome.

24 keywords...

hide…